Charity-funded Study of SFX-01 in Triple Negative Breast Cancer
11th July 2017
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that the Company's lead product, SFX-01, will be tested against triple negative breast cancer ("TNBC") in new preclinical research at the Manchester Cancer Research Centre, UK. This initiative is to be funded by a charitable donation from the Shine Bright Foundation, a UK charity focused on TNBC, to the University of Manchester, which is Evgen Pharma's long-standing research collaborator.
15th January 2018
8th January 2018